Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03796598 · ClinicalTrials.gov registry record · Phase 1
FMT in Cirrhosis and Hepatic Encephalopathy
A Phase 1 study of Cirrhosis and Hepatic Encephalopathy, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03796598 is a Phase 1 study of Cirrhosis and Hepatic Encephalopathy that has completed, run by VA Office of Research and Development. The registered enrollment target is 60 participants, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03796598, a Phase 1 study of Cirrhosis and Hepatic Encephalopathy, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients with end stage of liver disease or cirrhosis can develop confusion due to high ammonia and inflammation. This confusion is brought upon by changes in the bacteria in the bowels and may not respond to current standard of care treatments. Repeated episodes of confusion can make it difficult for patients to function and may result in multiple admissions to the hospital and burden on the family. The investigators have studied using a healthy person's stool to replace the bowel bacteria, called fecal microbial transplant, in small studies with good results. In this trial the investigators propose to perform these procedures using an upper and lower route in Veterans who suffer from this condition and follow them for safety and HE and related hospitalizations over 6 months. The investigators will compare this to placebo treatments and hope that this intervention can improve the health and daily functioning of affected patients.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fecal Microbial transplant Capsules
- DRUG Fecal Microbial Transplant Enema
Study Locations (1)
Virginia
- Hunter Holmes McGuire VA Medical Center, Richmond, VA - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-07-29 |
| Est. Completion | 2023-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03796598
The ClinicalTrials.gov registry entry for NCT03796598 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,408-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03796598 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT03796598 about?
NCT03796598 is a clinical study titled "FMT in Cirrhosis and Hepatic Encephalopathy". Patients with end stage of liver disease or cirrhosis can develop confusion due to high ammonia and inflammation. This confusion is brought upon by changes in the bacteria in the bowels and may not respond to current standard of care treatments. Repeated episodes of confusion can make it difficult f...
What is the current status of trial NCT03796598?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-07-29. Estimated completion is 2023-12-20.
What conditions does trial NCT03796598 study?
This clinical trial studies the following conditions: Cirrhosis, Hepatic Encephalopathy.
What interventions are being tested in trial NCT03796598?
The interventions under investigation include: Placebo (OTHER), Fecal Microbial transplant Capsules (DRUG), Fecal Microbial Transplant Enema (DRUG).
Who is sponsoring clinical trial NCT03796598?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03796598 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
RECRUITING · Phase 1
-
Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
RECRUITING · Phase 1
-
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
ACTIVE NOT RECRUITING · Phase 1
-
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis
ACTIVE NOT RECRUITING · Phase 1
-
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.